心血管病防治知识(下半月)
心血管病防治知識(下半月)
심혈관병방치지식(하반월)
XINXUEGUANBING FANGZHI ZHISHI
2014年
1期
44-46
,共3页
急性心肌梗死%溶栓治疗%临床疗效
急性心肌梗死%溶栓治療%臨床療效
급성심기경사%용전치료%림상료효
Acute myocardial infarction%Thrombolysis%Clinical effect
目的:探讨和分析采取静脉溶栓法治疗急性心肌梗死患者的临床效果。方法选取102例经笔者治疗的急性心肌梗死患者为研究对象,采取随机数字标记法将上述选取对象分成对照组和观察组,对照组患者采取常规治疗的方法进行治疗,观察组患者采取静脉溶栓的方法进行治疗,观察和分析两组对象的血管再通率以及治疗过程中不良反应的发生率。结果对照组和观察组血管再通的患者人数依次为33例和43例,再通率依次为66.0%和82.7%,两组上述指标对比有显著性差异(P<0.05);治疗过程中,对照组和观察组发生不良反应的患者人数依次为8例和3例,不良反应发生率依次为16.0%和5.8%,两组对比有显著性差异(P<0.05)。结论使用尿激酶药物,采取静脉溶栓的方式对急性梗死患者进行治疗,安全系数高,治疗效果好,而且经济实惠,值得在广大基层医院进行推广。
目的:探討和分析採取靜脈溶栓法治療急性心肌梗死患者的臨床效果。方法選取102例經筆者治療的急性心肌梗死患者為研究對象,採取隨機數字標記法將上述選取對象分成對照組和觀察組,對照組患者採取常規治療的方法進行治療,觀察組患者採取靜脈溶栓的方法進行治療,觀察和分析兩組對象的血管再通率以及治療過程中不良反應的髮生率。結果對照組和觀察組血管再通的患者人數依次為33例和43例,再通率依次為66.0%和82.7%,兩組上述指標對比有顯著性差異(P<0.05);治療過程中,對照組和觀察組髮生不良反應的患者人數依次為8例和3例,不良反應髮生率依次為16.0%和5.8%,兩組對比有顯著性差異(P<0.05)。結論使用尿激酶藥物,採取靜脈溶栓的方式對急性梗死患者進行治療,安全繫數高,治療效果好,而且經濟實惠,值得在廣大基層醫院進行推廣。
목적:탐토화분석채취정맥용전법치료급성심기경사환자적림상효과。방법선취102례경필자치료적급성심기경사환자위연구대상,채취수궤수자표기법장상술선취대상분성대조조화관찰조,대조조환자채취상규치료적방법진행치료,관찰조환자채취정맥용전적방법진행치료,관찰화분석량조대상적혈관재통솔이급치료과정중불량반응적발생솔。결과대조조화관찰조혈관재통적환자인수의차위33례화43례,재통솔의차위66.0%화82.7%,량조상술지표대비유현저성차이(P<0.05);치료과정중,대조조화관찰조발생불량반응적환자인수의차위8례화3례,불량반응발생솔의차위16.0%화5.8%,량조대비유현저성차이(P<0.05)。결론사용뇨격매약물,채취정맥용전적방식대급성경사환자진행치료,안전계수고,치료효과호,이차경제실혜,치득재엄대기층의원진행추엄。
Objective To investigate and analyze the clinical effect of intravenous thrombolysis in the treatment of acute myocardial infarction (AMI). Methods A total of 102 AMI patients treated in our hospital were included in the study. These subjects were randomly divided into control group and observation group. The control group received conventional treatment, while the observation group received intravenous thrombolysis. The treatment outcomes of the two groups were analyzed based on revascularization rate and incidence of adverse events. Results In the control group, 33 patients (66.0%) had revascularization, versus 43 patients (82.7%) in the observation group; there was significant difference in this index between the two groups (P<0.05). During treatment, 8 cases (16.0%) of the control group had adverse events, versus 3 cases (5.8%) of the observation group;there was significant difference in this index between the two groups (P<0.05). ConclusionIntravenous thrombolysis using urokinase has the advantages of high safety, good efficacy, and low cost in the treatment of AMI and holds promise for clinical application in primary hospitals.